Zuoxuan Duoba Pian (左旋多巴片)左旋多巴片

This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。

Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。

生产企业Manufacturer

主要成分Active Ingredients

药物知识说明

左旋多巴是一种在国家药监局注册认定的药品。该药品含有左旋多巴-b741429e等成分。

该药品关联的活性成分包括:左旋多巴Zuoxuan Duoba。这些成分信息来自国家药监局数据库。

该药品标注的生产企业为:北海阳光药业有限公司Chinese legal name: 北海阳光药业有限公司。

您可以探索含有相同成分的其他药品:左旋多巴-b741429e成分药品。

本页面内容来自国家药监局数据库,MedicineGraph在此基础上提供关系图谱和知识导航。

Medicine Knowledge

This medicine (original name: 左旋多巴片) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).

Active ingredients associated with this product: 左旋多巴Zuoxuan Duoba.

Manufacturers recorded for this product: 北海阳光药业有限公司Chinese legal name: 北海阳光药业有限公司.

Explore other medicines containing the same ingredient: 左旋多巴 productsProducts containing this recorded ingredient.

Source: MedicineGraph authoritative database. Relationships derived from registered product information.

这是什么What is this

  • 通用名/品名Recorded product name: 左旋多巴片Recorded Chinese name: 左旋多巴片
  • 剂型Dosage form: 片剂Tablets
  • 规格Specification: 0.25g0.25 g

本段仅展示注册/说明书已记录的身份属性,不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.

主要成分Ingredients

生产企业Manufacturer

  • 北海阳光药业有限公司Chinese legal name: 北海阳光药业有限公司

注册信息NMPA approval number

  • 批准文号NMPA approval number: 国药准字H45021569

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.

  • 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
  • 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
  • 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.

本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.

English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.

NMPA approval number

国药准字H45021569

Manufacturer

Chinese legal name: 北海阳光药业有限公司 (domestically manufactured)

Indications

English translation unavailable. The original Chinese source label remains available below.

Dosage and administration

English translation unavailable. The original Chinese source label remains available below.

Adverse reactions

English translation unavailable. The original Chinese source label remains available below.

Contraindications

English translation unavailable. The original Chinese source label remains available below.

Precautions

English translation unavailable. The original Chinese source label remains available below.

Storage

Keep sealed.

Specification

English translation unavailable. The original Chinese source label remains available below.

中文说明书原文Original Chinese source label

批准文号

国药准字H45021569

生产企业

北海阳光药业有限公司(国产)

适应症

本品用于帕金森病及帕金森综合症。

用法用量

口服给药: 1.开始一次250mg,一日2~4次,饭后服用。 2.以后视患者耐受情况,每隔3~7日增加一次剂量,增加范围为每日125~750mg,直至最理想的疗效为止,每日最大量6g,分4~6次服用。 3.脑炎后及老年患者应酌减剂量。

不良反应

1.不良反应较多,主要由于外周产生的多巴胺过多引起。
2.胃肠反应如恶心、呕吐、食欲不振,治疗初期,约80%病人产生。
3.用药3个月后可出现不安、失眠、幻觉等精神症状。
4.尚有体位性低血压、心律失常及不自主运动等。应注意调整剂量,必要时停药。

禁忌

严重心血管并器质性脑并内分泌失调及精神病患者禁用。

注意事项

1.早期出现恶心、呕吐、食欲不振。
2.体位性低血压,从卧位或坐位起立时眩晕。
3.精神不安、失眠、心律失常、不自主运动等,此时应注意调整剂量。
4.“开关现象”即突然多动不安,而后肌强直运动。
5.不宜与麻黄素、利血平、拟肾上素药、单胺氧化酶抑制剂合用。
6.支气管炎、肺气肿、有惊厥史、糖尿病、内分泌疾病、青光眼、肝肾功能不全、消化道溃疡病、精神病患者禁用。

贮藏

密封。

规格

0.25g

证据Evidence

  • 批准文号: 国药准字H45021569
  • rights: 本段为已核准说明书原文摘录(非改写、非AI摘要),非正式英文标签,亦不构成用药建议。

信息来源Source and scope

国家药品监督管理局(中国)药品注册数据。National Medical Products Administration (China) medicine-registration data.

范围:当前 MedicineGraph 注册记录及已记录的精确关系;非完整目录,亦不构成疗效等同主张,也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.